• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[神经退行性疾病中PET成像的最新进展]

[Recent Updates on PET Imaging in Neurodegenerative Diseases].

作者信息

Kim Yu Kyeong

出版信息

Taehan Yongsang Uihakhoe Chi. 2022 May;83(3):453-472. doi: 10.3348/jksr.2022.0052. Epub 2022 May 25.

DOI:10.3348/jksr.2022.0052
PMID:36238518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9514517/
Abstract

Over the past decades, the immense clinical need for early detection methods and treatments for dementia has become a priority worldwide. The advances in PET biomarkers play increasingly important roles in understanding disease mechanisms by demonstrating the protein pathology underlying dementia in the brain. Amyloid-β and tau deposition in PET images are now key diagnostic biomarkers for the Alzheimer's disease continuum. The inclusion of biomarkers in the diagnostic criteria has achieved a paradigm shift in facilitating early differential diagnosis, predicting disease prognosis, and influencing clinical management. Furthermore, images showing pathology could become prognostic as well as surrogate biomarkers in therapeutic trials. In this review, we focus on recent developments in radiotracers for amyloid-β and tau PET imaging in Alzheimer's disease and other neurodegenerative diseases. Further, we introduce their potential application as future perspectives.

摘要

在过去几十年里，对痴呆症早期检测方法和治疗的巨大临床需求已成为全球优先事项。正电子发射断层扫描（PET）生物标志物的进展通过展示大脑中痴呆症潜在的蛋白质病理学，在理解疾病机制方面发挥着越来越重要的作用。PET图像中的淀粉样蛋白-β和tau沉积现在是阿尔茨海默病连续体的关键诊断生物标志物。在诊断标准中纳入生物标志物在促进早期鉴别诊断、预测疾病预后和影响临床管理方面实现了范式转变。此外，显示病理学的图像在治疗试验中可能成为预后生物标志物以及替代生物标志物。在本综述中，我们重点关注用于阿尔茨海默病和其他神经退行性疾病的淀粉样蛋白-β和tau PET成像放射性示踪剂的最新进展。此外，我们介绍它们作为未来前景的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/1d813e98ed5e/jksr-83-453-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/6d62a04cf774/jksr-83-453-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/26384f221b4d/jksr-83-453-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/07d6a14a5527/jksr-83-453-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/dd7bd2ebdfa8/jksr-83-453-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/1d813e98ed5e/jksr-83-453-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/6d62a04cf774/jksr-83-453-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/26384f221b4d/jksr-83-453-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/07d6a14a5527/jksr-83-453-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/dd7bd2ebdfa8/jksr-83-453-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e193/9514517/1d813e98ed5e/jksr-83-453-g005.jpg

相似文献

1
[Recent Updates on PET Imaging in Neurodegenerative Diseases].[神经退行性疾病中PET成像的最新进展]
Taehan Yongsang Uihakhoe Chi. 2022 May;83(3):453-472. doi: 10.3348/jksr.2022.0052. Epub 2022 May 25.
2
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.阿尔茨海默病中的 Tau 生物标志物：迈向临床实践和试验的应用。
Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25.
3
Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.用于痴呆症中蛋白质病成像的正电子发射断层扫描示踪剂的最新进展
Front Aging Neurosci. 2022 Jan 3;13:751897. doi: 10.3389/fnagi.2021.751897. eCollection 2021.
4
In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.体内 tau PET 成像在痴呆中的应用：发病机制、示踪剂定量及临床研究结果的系统综述。
Ageing Res Rev. 2017 Jul;36:50-63. doi: 10.1016/j.arr.2017.03.002. Epub 2017 Mar 15.
5
FDG-PET and amyloid-PET imaging: the diverging paths.氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）与淀粉样蛋白正电子发射断层扫描（amyloid-PET）成像：分道扬镳之路。
Curr Opin Neurol. 2014 Aug;27(4):405-13. doi: 10.1097/WCO.0000000000000109.
6
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease.迈向阿尔茨海默病所致痴呆症的 tau PET 示踪剂临床应用。
Alzheimers Dement. 2021 Dec;17(12):1998-2008. doi: 10.1002/alz.12356. Epub 2021 May 13.
7
Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.阿尔茨海默病的神经影像学：聚焦于淀粉样蛋白和tau PET。
Jpn J Radiol. 2019 Nov;37(11):735-749. doi: 10.1007/s11604-019-00867-7. Epub 2019 Sep 6.
8
Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention.阿尔茨海默病中β淀粉样蛋白和tau蛋白的神经解剖学传播：对一级预防的启示
Brain Commun. 2020;2(1):fcaa007. doi: 10.1093/braincomms/fcaa007. Epub 2020 Feb 6.
9
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.血液磷酸化 tau 181 作为阿尔茨海默病的生物标志物：使用来自四个前瞻性队列的数据进行的诊断性能和预测模型研究。
Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5.
10
Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.生物标志物在临床环境中用于痴呆早期鉴别诊断和预后的交叉验证。
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):499-508. doi: 10.1007/s00259-015-3170-y. Epub 2015 Sep 4.

本文引用的文献

1
Mesial temporal tau in amyloid-β-negative cognitively normal older persons.淀粉样-β阴性认知正常老年人的内侧颞叶 tau。
Alzheimers Res Ther. 2022 Apr 8;14(1):51. doi: 10.1186/s13195-022-00993-x.
2
Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and Genotype: Importance of Striatal Amyloid.根据性别和基因型，阿尔茨海默病生物标志物的独特时间轨迹：纹状体淀粉样蛋白的重要性。
Front Aging Neurosci. 2022 Feb 7;14:829202. doi: 10.3389/fnagi.2022.829202. eCollection 2022.
3
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
基于生物标志物的阿尔茨海默病纵向 Tau 正电子发射断层扫描预测。
JAMA Neurol. 2022 Feb 1;79(2):149-158. doi: 10.1001/jamaneurol.2021.4654.
4
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.Donanemab（LY3002813）在阿尔茨海默病中的 1b 期研究：用 Florbetapir F18 成像测量脑淀粉样蛋白的快速和持续减少。
J Prev Alzheimers Dis. 2021;8(4):414-424. doi: 10.14283/jpad.2021.56.
5
Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study.阿尔茨海默病中使用 tau PET 进行 tau 病理学分期：一项纵向研究。
Transl Psychiatry. 2021 Sep 18;11(1):483. doi: 10.1038/s41398-021-01602-5.
6
Dual-phase F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer's disease.双时相 F-氟比洛芬 PET 提供阿尔茨海默病的脑灌注代理以及β淀粉样蛋白负担。
Neuroimage Clin. 2021;31:102773. doi: 10.1016/j.nicl.2021.102773. Epub 2021 Jul 24.
7
Evaluation of the early-phase [F]AV45 PET as an optimal surrogate of [F]FDG PET in ageing and Alzheimer's clinical syndrome.评估早期 [F]AV45 PET 作为衰老和阿尔茨海默病临床综合征中 [F]FDG PET 的最佳替代物。
Neuroimage Clin. 2021;31:102750. doi: 10.1016/j.nicl.2021.102750. Epub 2021 Jul 1.
8
A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.多中心比较[F]flortaucipir、[F]RO948 和 [F]MK6240 tau PET 示踪剂，以检测用于鉴别诊断的常见目标 ROI。
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2295-2305. doi: 10.1007/s00259-021-05401-4. Epub 2021 May 27.
9
Four distinct trajectories of tau deposition identified in Alzheimer's disease.阿尔茨海默病中tau 沉积的四种不同轨迹。
Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29.
10
Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum.大脑皮质下低灌注与阿尔茨海默病连续体中内嗅皮质的 tau-PET 相关。
Neurobiol Aging. 2021 Jun;102:111-118. doi: 10.1016/j.neurobiolaging.2021.02.003. Epub 2021 Feb 10.